Laser for retina disease goes to trial

Article

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

The prospective study, being conducted at King's College, University of London, enrolled 18 patients (29 eyes). All patients received treatments with the Ellex 2RT prototype laser and received follow-up examinations at three, six and 12-months.

At three months, the majority of patients demonstrated improvements in VA and central macular thickness (CMT), as measured by optical coherence tomography. CMT decreased in 55% of eyes and remained stable in 24%. An increase in CMT was seen in just 20% of eyes. Furthermore, micro-perimetry confirmed that there was no damage to photoreceptor cells.

Ellex now plans to conduct trials to determine whether the 2RT has potential as an early stage therapy for retinal diseases.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.